Targeted Oncology

FDA grants priority review to tabelecleucel for relapsed/refractory EBV+ PTLD, a critical step towards the first approved therapy for this severe posttransplant malignancy. PDUFA date Jan 10, 2026. #EBVPTLD #CellTherapy #FDA #Oncology hubs.li/Q03yZGCB0

Startling study finds high-mortality cancers are underfunded in US federal research, favoring incidence over death rates. This funding gap slows therapeutic advances for deadliest cancers. Read more: hubs.li/Q03yPw4B0

WATCH: John M. Burke, MD, gives his take on the FDA ODAC's votes on glofitamab in DLBCL and daratumumab in smoldering myeloma in this month's Chief Insights in Oncology. hubs.ly/Q03yN4dj0

WATCH: @ben_schlechter discusses the unmet needs and advent of immunotherapy in colorectal cancer treatment targetedonc.com/view/beyond-th…

Tara Graff, DO, discusses how recent ASCO updates, particularly the SEQUOIA study results, highlight the long-term efficacy of zanubrutinib in high-risk patients and represent the most significant advances in #CLL treatment from the meeting. @uihealthcare hubs.li/Q03wXgsw0

Big news in breast cancer treatment: a 10-year phase 3 study confirms long-term efficacy & safety of reduced-dose/partial-breast radiation. Comparable to standard treatment with low recurrence. Full article → hubs.li/Q03ytqWZ0

Luspatercept (Reblozyl) phase 3 INDEPENDENCE trial missed its primary endpoint for RBC transfusion independence but showed promising secondary benefits, like reduced transfusion burden & increased hemoglobin. hubs.li/Q03ycfyx0 #Myelofibrosis #Anemia #ClinicalTrials

Carboplatin/Paclitaxel to Immunotherapy Combinations: Evolving First-Line Options in Advanced #SCAC | @UTSWMedCenter @MoffittNews hubs.li/Q03wFyQ10

FDA issues CRL for RP1 in advanced melanoma. Concerns cited: interpretability of IGNYTE trial due to patient heterogeneity & confirmatory trial design questions. #Melanoma #FDA #DrugDevelopment hubs.li/Q03yhNkw0

WATCH: @rajshekharucms discusses the safety and tolerability of linvoseltamab with carfilzomib when used for the treatment of patients with relapsed/refractory multiple myeloma targetedonc.com/view/linvoselt…

Andrew H. Lipsky, MD, (@andrewlipskymd) and participants discussed balancing efficacy, safety, and patient preferences when choosing #CLL treatment. #leusm | @ColumbiaMed hubs.li/Q03xy8Sv0

Final OS data from FLAURA2 confirm osimertinib + platinum-based chemo significantly extends survival in 1L EGFRm NSCLC. A potential new standard of care. Read more: hubs.li/Q03y1gxQ0 #LungCancer #EGFRm #NSCLC #Oncology #ClinicalTrials

Panelist discusses how BTK inhibitors fit into real-world practice with community physicians often using monotherapy. #CLL hubs.li/Q03wFvf70

Shahzad Raza, MD, explains the rationale behind the REDIRECTT-1 study. #mmsm | @ClevelandClinic hubs.li/Q03xtpmN0

📢 Big news in breast cancer treatment! The FDA has granted Breakthrough Therapy Designation to T-DXd + pertuzumab for first-line HER2-positive metastatic breast cancer #BreastCancer #HER2Positive #CancerResearch Read more: targetedonc.com/view/t-dxd-bre…

Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma. #mmsm | @SarahCannonDocs hubs.li/Q03wFcN-0

In this video, Theresa Medina, MD, discusses the clinical potential of lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma. #melsm | @CUCancerCenter hubs.li/Q03x_-gV0